POWERING THE UK’S APPROACH TO ANTIMICROBIAL RESISTANCE
Antimicrobial Resistance (AMR) is one of the defining challenges of our time. An increasing number of infections caused by bacteria, fungi, parasites and viruses are becoming resistant to antimicrobial drugs and antibiotics, threatening to turn routine procedures and treatments like c-sections and chemotherapy into life-critical endeavours.
The UK has been at the forefront of efforts to battle AMR, recently publishing its 2040 Vision for tackling AMR and 5-year national action plan, and announcing a novel reimbursement model to accelerate investment in antibiotic development. Achieving sustained transformation, however, requires action across several fronts and ongoing cooperation with governments and industry alike. With the COVID-19 pandemic radically reshaping the world and testing the resilience of healthcare systems worldwide, it is crucial not to lose sight of the silent pandemic that is AMR.
Boosting innovation to curb AMR?
AMR Innovation Mission UK 2021
The AMR Innovation Mission UK 2021 aims to add to the global curbing of AMR by boosting joint early & translational research, R&D, clinical development, validation, registration and commercialisation of vaccines, microbial diagnostics and antimicrobial products.